Invention Grant
- Patent Title: 1,3,4-thiadiazole compounds and their use in treating cancer
-
Application No.: US15363018Application Date: 2016-11-29
-
Publication No.: US09938265B2Publication Date: 2018-04-10
- Inventor: Johannes Wilhelmus Maria Nissink , Maurice Raymond Verschoyle Finlay , Mark David Charles , Matt Wood
- Applicant: AstraZeneca AB , Cancer Research Technology Limited
- Applicant Address: SE GB
- Assignee: AstraZeneca AB,Cancer Research Technology Limited
- Current Assignee: AstraZeneca AB,Cancer Research Technology Limited
- Current Assignee Address: SE GB
- Agent Daniel Kopp
- Main IPC: C07D417/14
- IPC: C07D417/14
Abstract:
A compound of Formula (I): or a pharmaceutically acceptable salt thereof, where: Q can be 5-methylpyridazin-3-yl,5-chloropyridazin-3-yl, 6-methylpyridazin-3-yl, or 6-fluoropyridazin-3-yl; R can be hydrogen, fluoro, or methoxy; R1 can be hydrogen, methoxy, difluoromethoxy, or trifluoromethoxy; and R2 can be methyl or ethyl. The compound of formula (I) can inhibit glutaminase, e.g., GLS1.
Public/Granted literature
- US20170152254A1 1,3,4-Thiadiazole Compounds and Their Use in Treating Cancer Public/Granted day:2017-06-01
Information query
